Lifestyle Eating and Performance (LEAP) Program for the Treatment of Irritable Bowel Syndrome (IBS) - Trial NCT05178017
Access comprehensive clinical trial information for NCT05178017 through Pure Global AI's free database. This phase not specified trial is sponsored by Oxford Biomedical Technologies, Inc. and is currently Recruiting. The study focuses on IBS - Irritable Bowel Syndrome. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Leukocyte Activation Assay (LAA-MRT) / Lifestyle Eating and Performance (LEAP) program
Interventional
diagnostic test
Sponsor & Location
Oxford Biomedical Technologies, Inc.
Timeline & Enrollment
N/A
Sep 01, 2021
Dec 01, 2023
Primary Outcome
Inflammatory blood markers
Summary
A three month follow-up study to evaluate the effectiveness of a tailored anti-inflammatory
 eating plan guided by a registered dietitian to treat irritable bowel syndrome.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05178017
Non-Device Trial